Care Clinic

Red Deer, Alberta T4P1K4

4 studies enrolling now · 30 studies all time

What they study most

Active Nonsegmental Vitiligo, Alopecia Areata, Atopic Dermatitis, Atopic Dermatitis, Unspecified, C. Diff Infection, C.Difficile Diarrhea, CDI, Chronic Kidney Disease, Chronic Spontaneous Urticaria, Clostridioides Difficile, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence

Studies at this site

• VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Recruiting now
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Recruiting now
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Recruiting now
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. — Recruiting now
• A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Running, not enrolling
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age — Completed
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Running, not enrolling
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis — Running, not enrolling
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Running, not enrolling
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo — Completed
• A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Running, not enrolling
• A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis — Completed
• A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — Completed
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema — Completed
• A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection — Stopped early
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older — Completed
• Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention — Stopped early
• Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults — Completed
• A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease — Completed
• A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease — Completed
• A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) — Stopped early
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 — Withdrawn before enrolling
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults — Running, not enrolling